Voriconazole for chronic pulmonary aspergillosis: A prospective multicenter trial

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 11, 2012, Pages 3231-3239

  Cadranel, J ^a,b   Philippe, B ^c   Hennequin, C ^b,d,e   Bergeron, A ^f   Bergot, E ^g,h   Bourdin, A ^i,j   Cottin, V ^k,l   Jeanfaivre, T ^m   Godet, C ⁿ   Pineau, M ^o   Germaud, P ^p  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE HOSPITALIER RENÉ DUBOS   (France)

^d INSERM   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CHU CÔTE DE NACRE   (France)

^h UNIVERSITÉ DE CAEN   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF MONTPELLIER   (France)

^k LOUIS PRADEL HOSPITAL   (France)

^l UNIVERSITÉ LYON 1   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ POITIERS UNIVERSITY HOSPITAL   (France)

^o PFIZER INC   (United States)

^p CHU de Nantes   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PRECIPITIN; VORICONAZOLE;

ADULT; AGED; AMNESIA; ANOREXIA; ARTICLE; ASPERGILLUS FUMIGATUS; BLURRED VISION; CHILL; CHOLESTASIS; CHRONIC CAVITARY ASPERGILLOSIS; CHRONIC LUNG DISEASE; CHRONIC NECROTIZING ASPERGILLOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DECREASED APPETITE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; FUNGUS CULTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL CONDITION DETERIORATION; HEADACHE; HUMAN; HYPONATREMIA; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INSOMNIA; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; QUALITY OF LIFE; RESPIRATORY TRACT EXAMINATION; SEROLOGY; SIDE EFFECT; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CHRONIC DISEASE; DRUG TOXICITY; ENDOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ASPERGILLOSIS; PYRIMIDINES; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TRIAZOLES;

EID: 84867991822     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1690-y     Document Type: Article

References (29)

1. Denning DW, Riniotis K, Dobrashian R, Sambatakou H (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265-S280
2. Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37:865-872
3. Soubani AO, Chandrasekar PH (2002) The clinical spectrum of pulmonary aspergillosis. Chest 121:1988-1999
4. Uffredi ML, Mangiapan G, Cadranel J, Kac G (2003) Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 22:457-462
5. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB (1997) Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 112:541-548
6. Dupont B (1990) Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 23:607-614
7. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563-571
8. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
9. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J et al (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122-1131
10. Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A (2011) An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. Eur J Clin Microbiol Infect Dis 31:1173-1179
11. Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46:1032-1037
12. Herbrecht R (2004) Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2:485-497
13. Krishnan S, Manavathu EK, Chandrasekar PH (2005) A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 55:914-920
14. Capitano B, Potoski BA, Husain S, Zhang S, Paterson DL, Studer SM et al (2006) Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 50:1878-1880
15. Sambatakou H, Dupont B, Lode H, Denning DW (2006) Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 119:527.e17-527.e24
16. Jain LR, Denning DW (2006) The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 52:e133-e137
17. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131:1435-1441
18. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2012) Amphotericin B and Aspergillus spp.: rationale for the EUCAST clinical breakpoints, v1.0, January 2012. http://www.eucast.org. Accessed 24 May 2012
19. Verweij PE, Howard SJ, Melchers WJ, Denning DW (2009) Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12:141-147
20. European Medicines Agency (EMA) (2009) Vfend: summary of product characteristics (revision 17). Available online at: http://www.ema.europa.eu/ humandocs/Humans/EPAR/vfend/vfend.htm. Accessed 9 September 2011
21. Bart-Delabesse E, Humbert JF, Delabesse E, Bretagne S (1998) Microsatellite markers for typing Aspergillus fumigatus isolates. J Clin Microbiol 36:2413-2418
22. Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C (2012) In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. Int J Antimicrob Agents 39:440-443
23. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360
24. De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N et al (1988) The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 31:476-485
25. Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW (2010) Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 51:1383-1391
26. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R et al; Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG) et al (2010) Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 61:410-418
27. Izumikawa K, Ohtsu Y, Kawabata M, Takaya H, Miyamoto A, Sakamoto S et al (2007) Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 45:273-278
28. Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A et al (2004) A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36:372-379
29. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201-211